QIAGEN Reports Q3 Revenue Growth, Suspends 2026 Guidance Amid EQT Offer
QIAGEN reported Q3 revenue of $548 million, up 2.8% and above its previous outlook. Adjusted diluted EPS was $0.65 versus $0.61 a year earlier; GAAP EPS was $0.51 versus $0.60. The company suspended its 2026 guidance amid EQT Private Equity’s pending €46.50-per-share offer.
QIAGEN NV announced its Q3 2026 financial results, reporting a 2.8% increase in revenue to $548 million, which exceeded the company's previous outlook. Adjusted diluted EPS rose to $0.65 from $0.61 in the prior year, while GAAP EPS declined to $0.51 from $0.60. Concurrently, the company suspended its 2026 financial guidance due to the pending acquisition offer from EQT Private Equity, valued at €46.50 per share. Additionally, shareholders approved the appointment of CEO Jonathan M.
Pratt to the Managing Board through the 2027 annual meeting. Recent filings also indicated that BlackRock increased its stake in the company to 12.13%.